Haemonetics Projects 4%-7% Revenue, EPS Growth for FY27
Summary
Haemonetics has issued its financial outlook for fiscal year 2027, projecting a 4% to 7% increase in both revenue and adjusted earnings per share. This forward-looking guidance provides investors with the company's official expectations for its future financial performance. Such projections are critical for valuation models and can significantly influence investor sentiment and stock price. This new guidance is a material update, as it was not detailed in the recent 8-K filing or the prior Q3 report. Traders will be closely watching subsequent earnings calls and reports for updates on these targets and any factors that could impact the company's ability to achieve this growth.
At the time of this announcement, HAE was trading at $54.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $47.32 to $87.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.